Foghorn Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Foghorn Therapeutics Inc. (Nasdaq: FHTX) is a clinical-stage precision therapeutics biotechnology company pioneering a new class of medicines targeting the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company identifies, validates, and drugs targets within this system to correct abnormal gene expression. Foghorn's primary focus is on oncology, developing therapies for genetically determined dependencies in various cancers, including non-small cell lung cancer (NSCLC), endometrial, cervical, ovarian, bladder, and hematological malignancies. The company's flagship program is FHD-909 (LY4050784), a selective ATPase inhibitor of BRM being co-developed in a 50/50 U.S. cost-share collaboration with Eli Lilly and Company.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the Phase 1 dose-escalation trial of FHD-909 (LY4050784), a first-in-class oral selective SMARCA2 inhibitor, targeting SMARCA4-mutant cancers with a primary focus on non-small cell lung cancer (NSCLC).
Expected impact: Provides clinical validation of the synthetic lethal strategy targeting SMARCA2 in SMARCA4-mutant tumors.
Prioritizing and advancing wholly-owned selective protein degrader programs, specifically targeting CBP (FHT-171) for ER+ breast cancer and EP300 for hematological malignancies (multiple myeloma and DLBCL).
Expected impact: Establishes a proprietary clinical-stage pipeline of highly selective degraders that avoid the dose-limiting toxicities of dual CBP/EP300 inhibition.
Developing first-in-class cereblon-based bifunctional degraders targeting ARID1B, a major synthetic lethal target implicated in up to 5% of all solid tumors.
Expected impact: Addresses a challenging, non-enzymatic target with potential for oral bioavailability in endometrial, gastric, bladder, and lung cancers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to apply Foghorn's Gene Traffic Control platform to create novel oncology medicines, including a 50/50 U.S. co-development and co-commercialization agreement for the selective SMARCA2 program (including FHD-909) and an additional undisclosed target, plus three discovery programs.
Terms: $300 million upfront cash consideration and an $80 million equity investment at $20 per share received at inception. Foghorn is eligible to receive up to $1.3 billion in potential development and commercialization milestones, plus tiered royalties on ex-U.S. sales.